Drugs / TOP1288
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03071081 | Feb → Jun 2017 | ulcerative colitis | Topivert Pharma Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02463045 | May 2015 → Jul 2016 | ulcerative colitis | Topivert Pharma Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02888379 | Sep 2016 → Jun 2017 | ulcerative colitis | Topivert Pharma Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TOP1288 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02888379 ↗ |
| Action | Inhibit | “TOP1288, a narrow spectrum protein kinase inhibitor” NCT02463045 ↗ |
| Modality | Small molecule | “TOP1288, a narrow spectrum protein kinase inhibitor” NCT02463045 ↗ |
| Route | Rectal | “TOP1288 given rectally has a local anti-inflammatory action in experimental models of UC.” NCT02463045 ↗ |